The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Efficacy and Safety of Leptin-Replacement Therapy and Possible Mechanisms of Leptin Actions in Patients with Generalized Lipodystrophy
Abstract
BACKGROUND: Lack of leptin is implicated in insulin resistance and other metabolic abnormalities in generalized lipodystrophy; however, the efficacy, safety, and underlying mechanisms of leptin-replacement therapy in patients with generalized lipodystrophy remain unclear. METHODS: Seven Japanese patients with generalized lipodystrophy, two acquired and five congenital type, were treated with the physiological replacement dose of recombinant leptin during an initial 4-month hospitalization followed by outpatient follow-up for up to 36 months. RESULTS: The leptin-replacement therapy with the twice-daily injection dramatically improved fasting glucose (mean +/- SE, 172 +/- 20 to 120 +/- 12 mg/dl, P < 0.05) and triglyceride levels (mean +/- SE, 700 +/- 272 to 260 +/- 98 mg/dl, P < 0.05) within 1 wk. The leptin-replacement therapy reduced insulin resistance evaluated by euglycemic clamp method and augmented insulin secretion at glucose tolerance test with different responses between acquired and congenital types. Improvement of the fatty liver was also observed. The efficacy and safety of the once-daily injection were comparable to those of the twice-daily injection. The leptin-replacement therapy ameliorated macro- and microalbuminuria and showed no deterioration of neuropathy and retinopathy of these patients. The leptin-replacement therapy is beneficial to diabetic complications and lipodystrophic ones. Two patients developed antileptin antibodies but not neutralizing antibodies. The therapy was well tolerated, and its effects were maintained for up to 36 months without any notable adverse effects such as hypoglycemia, high blood pressure, or reduction of bone mineral density. CONCLUSIONS: The present study demonstrates the efficacy and safety of the long-term leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247
Self-citationLeptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S., & Goldstein, J. L. (1999) · Nature · doi:10.1038/43448 · Cited by 1,038 · cited 3×
“We and others demonstrated that the leptin administration or transgenic overexpression of leptin reverses the metabolic abnormalities in different mouse models of lipodystrophy, indicating that the metabolic abnormalities in lipoatrophic patients are caused mainly by a shortage of leptin (16, 17).”
BackgroundResultInfluentialLeptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215001 · Cited by 800 · cited 1×
“Fat accumulation in the insulin target organs, which causes so-called lipotoxicity, is considered to be one of the mechanisms for insulin resistance in patients with lipodystrophy (35).”
BackgroundSelf-citationAcute stimulation of glucose metabolism in mice by leptin treatment
Kamohara, S., Burcelin, R., Halaas, J. L., Friedman, J. M., & Charron, M. J. (1997) · Nature · doi:10.1038/38717 · Cited by 708
Long-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy
Javor, E. D., Cochran, E. K., Musso, C., Young, J. R., DePaoli, A. M., & Gorden, P. (2005) · Diabetes · doi:10.2337/diabetes.54.7.1994 · Cited by 226
Self-citationMusso, C., Cochran, E., Javor, E., Young, J., DePaoli, A. M., & Gorden, P. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.021 · Cited by 146
Self-citationJavor, E. D., Moran, S. A., Young, J. R., Cochran, E. K., DePaoli, A. M., Oral, E. A., Turman, M. A., Blackett, P. R., Savage, D. B., O’Rahilly, S., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032140 · Cited by 114
Self-citationChanges in body composition in patients with severe lipodystrophy after leptin replacement therapy
Moran, S. A., Patten, N., Young, J. R., Cochran, E., Sebring, N., Reynolds, J., Premkumar, A., Depaoli, A. M., Skarulis, M. C., Oral, E. A., et al. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.019 · Cited by 96
Self-citationMetabolic and endocrine studies in a case of lipoatrophic diabetes
Rossini, A. A., Self, J., Aoki, T. T., Goldman, R. F., Newmark, S. R., Meguid, M. M., Soeldner, J. S., & Cahill, G. F. (1977) · Metabolism · doi:10.1016/0026-0495(77)90085-3 · Cited by 28 · cited 1×
“Generalized lipodystrophy is a heterogeneous group of diseases characterized by a profound deficiency of adipose tissue (9) and is commonly associated with severe insulinresistant diabetes, hypertriglyceridemia, and fatty liver (10, 11).”
Background
Cited by
Manna, P., & Jain, S. K. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0095 · Cited by 1,145
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
Brown, R. J., Araujo-Vilar, D., Cheung, P. T., Dunger, D., Garg, A., Jack, M., Mungai, L., Oral, E. A., Patni, N., Rother, K. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2466 · Cited by 529
Biochemistry, physiology, and genetics of GPAT, AGPAT, and lipin enzymes in triglyceride synthesis
Takeuchi, K., & Reue, K. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90958.2008 · Cited by 463
Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
Argo, C. K., & Caldwell, S. H. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.005 · Cited by 389
Ravussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 332
Direct and indirect effects of leptin on adipocyte metabolism
Harris, R. B. S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.009 · Cited by 316
Leptin revisited: its mechanism of action and potential for treating diabetes
Coppari, R., & Bjørbæk, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3757 · Cited by 293
Qureshi, K. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i26.3540 · Cited by 283
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Hedbacker, K., Birsoy, K., Wysocki, R. W., Asilmaz, E., Ahima, R. S., Farooqi, I. S., & Friedman, J. M. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.007 · Cited by 280
Congenital generalized lipodystrophies—new insights into metabolic dysfunction
Patni, N., & Garg, A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.123 · Cited by 261
Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
Moon, H.-S., Dalamaga, M., Kim, S.-Y., Polyzos, S. A., Hamnvik, O.-P., Magkos, F., Paruthi, J., & Mantzoros, C. S. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1053 · Cited by 258
Lipodystrophy: pathophysiology and advances in treatment
Fiorenza, C. G., Chou, S. H., & Mantzoros, C. S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.199 · Cited by 255
Leptin in nonalcoholic fatty liver disease: A narrative review
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.012 · Cited by 235
Leptin applications in 2015: what have we learned about leptin and obesity?
Farr, O. M., Gavrieli, A., & Mantzoros, C. S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000184 · Cited by 233
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Selective leptin resistance revisited
Mark, A. L. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00180.2013 · Cited by 162
“(30) evaluated the efficacy and safety of leptin-replacement therapy from 4 mo to 3 yr in seven Japanese patients with leptin deficiency caused by generalized lipodystrophy.”
Mulligan, K., Khatami, H., Schwarz, J.-M., Sakkas, G. K., DePaoli, A. M., Tai, V. W., Wen, M. J., Lee, G. A., Grunfeld, C., & Schambelan, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1588 · Cited by 127
Self-citationEffects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Tang, Y., Huang, J., Zhang, W. Y., Qin, S., Yang, Y. X., Ren, H., Yang, Q.-B., & Hu, H. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819878046 · Cited by 85
Inherited lipodystrophies and hypertriglyceridemia.
Simha, V., & Garg, A. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832d4a33 · Cited by 67
Effects of Metreleptin in Pediatric Patients With Lipodystrophy
Brown, R. J., Meehan, C. A., Cochran, E., Rother, K. I., Kleiner, D. E., Walter, M., & Gorden, P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3628 · Cited by 65
Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
Filip, R., Radzki, R., & Bieńko, M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s170533 · Cited by 60
Tanaka, T., Masuzaki, H., Yasue, S., Ebihara, K., Shiuchi, T., Ishii, T., Arai, N., Hirata, M., Yamamoto, H., Hayashi, T., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.04.004 · Cited by 62
Metadata
- Authors
- Ebihara, K., Kusakabe, T., Hirata, M., Masuzaki, H., Miyanaga, F., Kobayashi, N., Tanaka, T., Chusho, H., Miyazawa, T., Hayashi, T., Hosoda, K., Ogawa, Y., DePaoli, A. M., Fukushima, M., & Nakao, K.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-11-21
- Volume
- 92
- Issue
- 2
- Pages
- 532-541
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2064611710
- Cited by
- 232
- References
- 10
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.